Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plan to be flexible: a commentary on adaptive designs.

Weichung Joe Shih1

  • 1Department of Biostatistics, School of Public Health, University of Medicine and Dentistry of New Jersey, USA. shihwj@umdnj.edu

Biometrical Journal. Biometrische Zeitschrift
|September 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

The Lancet. Haematology·2025
Same author

Two-stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers.

Statistics in biopharmaceutical research·2025
Same author

Monitoring Ongoing Clinical Trials under Fractional Brownian Motion with Drift.

Statistics in biopharmaceutical research·2025
Same author

PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.

Annals of hematology·2025
Same author

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.

Annals of hematology·2024
Same author

A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.

Infectious diseases and therapy·2024
Same journal

Comparison of Different Methods for the Meta-Analysis of Diagnostic Test Accuracy Studies-A Simulation Study.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

This discussion covers adaptive clinical trial designs, focusing on nested repeated confidence intervals and seamless Phase II/III trials with interim hypothesis selection. These methods enhance trial efficiency and flexibility in drug development.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmaceutical Research

Background:

  • Adaptive clinical trial designs offer flexibility over traditional methods.
  • Seamless Phase II/III trials allow for early decision-making and resource optimization.
  • Noninferiority and superiority switching requires robust statistical frameworks.

Discussion:

  • The papers explore nested repeated confidence intervals for adaptive superiority/noninferiority switching.
  • General concepts and practical applications of confirmatory seamless Phase II/III trials are presented.
  • Hypothesis selection at interim analysis is a key feature of these advanced designs.

Key Insights:

  • Nested confidence intervals provide a structured approach for adaptive trial modifications.

Related Experiment Videos

  • Seamless designs integrate multiple trial phases, improving efficiency.
  • Interim hypothesis selection requires careful statistical planning to maintain trial integrity.

    • Outlook:

    • Further research into optimizing adaptive designs for complex trial scenarios is warranted.
    • Implementation of these advanced designs can accelerate drug development timelines.
    • Statistical methodologies for adaptive trials are crucial for regulatory acceptance.